Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Goodall

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
The Lancet. HIV|November 29, 2015
Prevalence, incidence, and associated risk factors of tuberculosis in children with HIV living in the UK and Ireland (CHIPS): a cohort studyAnna Turkova, Elizabeth Chappell, Ali Judd, et al.
The Journal of Antimicrobial Chemotherapy|March 18, 2014
Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in UgandaR L Goodall, D T Dunn, T Pattery, et al.
HIV Medicine|May 3, 2021
Mortality and AIDS-defining events among young people following transition from paediatric to adult HIV care in the UKH Asad, I J Collins, R L Goodall, et al.
AIDS Research and Human Retroviruses|August 11, 2015
Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East AfricaKatherine A Sutherland, Ruth L Goodall, Adele McCormick, et al.
BMC Infectious Diseases|February 23, 2017
The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial dataDavid I Dolling, Ruth L Goodall, Michael Chirara, et al.
Lancet (London, England)|July 25, 2006
Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial, P Yeni, D A Cooper, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 6, 2010
Evolution of drug resistance during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoringFred Lyagoba, David T Dunn, Deenan Pillay, et al.
The Journal of Infectious Diseases|November 27, 2009
Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus AbacavirNicaise Ndembi, Nicasie Ndembi, Ruth L Goodall, et al.
JAMA|July 24, 2012
Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trialNicholas I Paton, Ruth L Goodall, David T Dunn, et al.
The Lancet. Respiratory Medicine|October 4, 2024
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trialRuth L Goodall, Andrew J Nunn, Sarah K Meredith, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
The Lancet. HIV|November 29, 2015
Prevalence, incidence, and associated risk factors of tuberculosis in children with HIV living in the UK and Ireland (CHIPS): a cohort studyAnna Turkova, Elizabeth Chappell, Ali Judd, et al.
The Journal of Antimicrobial Chemotherapy|March 18, 2014
Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in UgandaR L Goodall, D T Dunn, T Pattery, et al.
HIV Medicine|May 3, 2021
Mortality and AIDS-defining events among young people following transition from paediatric to adult HIV care in the UKH Asad, I J Collins, R L Goodall, et al.
AIDS Research and Human Retroviruses|August 11, 2015
Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East AfricaKatherine A Sutherland, Ruth L Goodall, Adele McCormick, et al.
BMC Infectious Diseases|February 23, 2017
The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial dataDavid I Dolling, Ruth L Goodall, Michael Chirara, et al.
Lancet (London, England)|July 25, 2006
Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial, P Yeni, D A Cooper, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 6, 2010
Evolution of drug resistance during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoringFred Lyagoba, David T Dunn, Deenan Pillay, et al.
The Journal of Infectious Diseases|November 27, 2009
Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus AbacavirNicaise Ndembi, Nicasie Ndembi, Ruth L Goodall, et al.
JAMA|July 24, 2012
Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trialNicholas I Paton, Ruth L Goodall, David T Dunn, et al.
The Lancet. Respiratory Medicine|October 4, 2024
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trialRuth L Goodall, Andrew J Nunn, Sarah K Meredith, et al.
Pageof 9